Document 0909
 DOCN  M9440909
 TI    Current management of hemophilia B.
 DT    9404
 AU    Roberts HR; Eberst ME; Department of Medicine, University of North
       Carolina at Chapel; Hill.
 SO    Hematol Oncol Clin North Am. 1993 Dec;7(6):1269-80. Unique Identifier :
       AIDSLINE MED/94124391
 AB    The management of hemorrhagic episodes in patients with hemophilia B is
       in transition as a result of the availability of new products for
       replacement therapy. Although the basic principles of therapy have not
       changed, the new highly purified Factor IX concentrates, AlphaNine and
       Mononine, represent a break-through, as they appear to be safe in terms
       of viral transmission and thromboembolic side-effects. These products
       are now widely available, and although expensive, are regarded by some
       physicians as the preferred therapy for Hemophilia B. Less pure and less
       expensive Factor IX products, however, are also available and can be
       used safely in previously treated patients who have already been exposed
       to the hepatitis viruses.
 DE    Christmas Disease/COMPLICATIONS/*DRUG THERAPY  Disseminated
       Intravascular Coagulation/ETIOLOGY  Factor IX/ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/ANTAGONISTS &  INHIB/*THERAPEUTIC USE
       Hepatitis/ETIOLOGY  Human  HIV Infections/ETIOLOGY  Isoantibodies/BLOOD
       Thromboembolism/ETIOLOGY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).